Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings
U.S. stocks tumbled: Nasdaq -4.5%, S&P 500 -3.3%, Dow -2.5%. Cardinal Health rose on strong results; AppLovin surged 32%, while Veracyte fell 55%.
Stocks · News reference
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Xeris Biopharma Holdings Q3 2026 Earnings Call Transcript
Xeris Biopharma Holdings (NASDAQ:XERS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access
Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Xeris Biopharma announced its third-quarter 2026 financial results, reporting a 44% year-over-year revenue increase to $107 million and raising its full-year 2026 and 2030 revenue outlooks.
8-K filing — Xeris Biopharma Holdings, Inc. (XERS)
Filed: 2026-11-05 AccNo: 0001867096-26-000114 Size: 343 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Xeris Biopharma Appoints Menassie M. Taddese to Board of Directors
Xeris Biopharma Holdings, Inc. has appointed Menassie M. Taddese to its Board of Directors, effective November 2, 2026.
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Xeris Biopharma Holdings, Inc. has scheduled the release of its third quarter 2026 financial results and business updates for November 5, 2026.